See more : 10x Genomics, Inc. (TXG) Income Statement Analysis – Financial Results
Complete financial analysis of Orthocell Limited (OCC.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orthocell Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- CoinShares International Limited (CS.ST) Income Statement Analysis – Financial Results
- SAG Holdings Ltd (SAG) Income Statement Analysis – Financial Results
- TagMaster AB (publ) (TAGM-B.ST) Income Statement Analysis – Financial Results
- Data Storage Corporation (DTSTW) Income Statement Analysis – Financial Results
- Cairo Mezz PLC (CMZZF) Income Statement Analysis – Financial Results
Orthocell Limited (OCC.AX)
About Orthocell Limited
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.32M | 4.24M | 1.53M | 1.02M | 719.52K | 945.66K | 619.18K | 529.82K | 666.50K | 790.43K | 691.41K | 524.28K |
| Cost of Revenue | 1.63M | 1.18M | 699.20K | 718.08K | 725.92K | 732.34K | 469.89K | 438.14K | 497.59K | 652.86K | 597.15K | 482.17K |
| Gross Profit | 3.69M | 3.06M | 832.52K | 299.88K | -6.40K | 213.32K | 149.29K | 91.68K | 168.91K | 137.57K | 94.25K | 42.11K |
| Gross Profit Ratio | 69.39% | 72.13% | 54.35% | 29.46% | -0.89% | 22.56% | 24.11% | 17.30% | 25.34% | 17.40% | 13.63% | 8.03% |
| Research & Development | 8.67M | 7.60M | 6.82M | 7.34M | 5.47M | 5.59M | 4.63M | 3.91M | 3.37M | 733.08K | 686.12K | 450.75K |
| General & Administrative | 3.61M | 4.25M | 2.24M | 3.25M | 2.56M | 2.02M | 2.02M | 1.78M | 1.60M | 894.74K | 498.37K | 415.86K |
| Selling & Marketing | 3.09M | 1.71M | 3.30M | 1.46M | 1.44M | 1.28M | 1.79M | 1.06M | 983.66K | 970.67K | 571.96K | 524.64K |
| SG&A | 6.70M | 5.77M | 5.54M | 4.63M | 3.99M | 3.30M | 3.81M | 2.85M | 2.59M | 5.12M | 2.66M | 2.15M |
| Other Expenses | 0.00 | 79.20K | 189.94K | 38.63K | 82.94K | 141.20K | 265.03K | 511.02K | 458.87K | 776.51K | 1.11M | 0.00 |
| Operating Expenses | 15.37M | 13.37M | 12.36M | 11.97M | 9.46M | 8.60M | 8.18M | 6.25M | 5.52M | 5.16M | 2.82M | 1.39M |
| Cost & Expenses | 17.00M | 14.55M | 13.06M | 12.69M | 10.19M | 9.34M | 8.65M | 6.69M | 6.02M | 5.81M | 3.42M | 1.87M |
| Interest Income | 1.03M | 850.79K | 84.13K | 199.24K | 116.39K | 10.82K | 18.47K | 35.75K | 61.84K | 123.37K | 15.11K | 24.56K |
| Interest Expense | 60.53K | 30.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 517.08K | 554.12K | 348.62K | 435.65K | 260.51K | 218.72K | 193.32K | 147.75K | 100.18K | 59.36K | 37.83K | 44.40K |
| EBITDA | -11.68M | -9.93M | -11.52M | -11.67M | -9.25M | -8.53M | -8.29M | -6.52M | -5.81M | -5.80M | -3.31M | -1.30M |
| EBITDA Ratio | -219.76% | -229.92% | -729.64% | -1,103.54% | -1,279.86% | -877.44% | -1,265.96% | -1,135.62% | -788.34% | -628.08% | -389.05% | -248.62% |
| Operating Income | -11.68M | -10.31M | -11.52M | -11.67M | -9.47M | -8.52M | -8.03M | -6.16M | -5.35M | -5.02M | -2.73M | -1.35M |
| Operating Income Ratio | -219.76% | -242.98% | -752.40% | -1,146.34% | -1,316.07% | -900.57% | -1,297.18% | -1,163.51% | -803.37% | -635.59% | -394.52% | -257.09% |
| Total Other Income/Expenses | 1.45M | 929.99K | 274.07K | 237.87K | 413.83K | 293.71K | 283.50K | 546.77K | 493.08K | 812.92K | 543.85K | 24.56K |
| Income Before Tax | -10.23M | -9.41M | -11.25M | -11.43M | -9.06M | -8.38M | -8.01M | -6.13M | -5.29M | -4.90M | -2.71M | -1.32M |
| Income Before Tax Ratio | -192.51% | -221.79% | -734.50% | -1,122.97% | -1,258.55% | -886.20% | -1,293.53% | -1,156.14% | -794.10% | -619.98% | -392.33% | -252.41% |
| Income Tax Expense | -3.05M | -3.16M | -2.14M | -2.39M | -2.90M | 2.53M | 2.25M | 1.95M | 1.51M | 1.16M | 530.43K | 0.00 |
| Net Income | -7.18M | -6.25M | -9.11M | -9.04M | -6.15M | -5.85M | -5.76M | -4.18M | -3.78M | -3.74M | -2.18M | -1.32M |
| Net Income Ratio | -135.10% | -147.26% | -594.53% | -887.76% | -854.88% | -618.85% | -929.80% | -788.46% | -567.87% | -473.50% | -315.62% | -252.41% |
| EPS | -0.04 | -0.03 | -0.05 | -0.05 | -0.04 | -0.05 | -0.06 | -0.04 | -0.04 | -0.05 | -0.06 | -0.04 |
| EPS Diluted | -0.04 | -0.03 | -0.05 | -0.05 | -0.04 | -0.05 | -0.05 | -0.04 | -0.04 | -0.05 | -0.06 | -0.04 |
| Weighted Avg Shares Out | 199.48M | 197.21M | 194.67M | 186.85M | 171.00M | 118.37M | 104.68M | 96.96M | 87.97M | 74.85M | 35.02M | 34.57M |
| Weighted Avg Shares Out (Dil) | 202.01M | 197.21M | 194.67M | 186.85M | 171.00M | 118.37M | 105.73M | 96.96M | 87.97M | 75.66M | 35.02M | 34.57M |
Source: https://incomestatements.info
Category: Stock Reports